APA
Czuczman M. S., Leonard J. P., Jung S., Johnson J. L., Hsi E. D., Byrd J. C. & Cheson B. D. (112018). Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness. : Annals of oncology : official journal of the European Society for Medical Oncology.
Chicago
Czuczman M S, Leonard J P, Jung S, Johnson J L, Hsi E D, Byrd J C and Cheson B D. 112018. Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness. : Annals of oncology : official journal of the European Society for Medical Oncology.
Harvard
Czuczman M. S., Leonard J. P., Jung S., Johnson J. L., Hsi E. D., Byrd J. C. and Cheson B. D. (112018). Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness. : Annals of oncology : official journal of the European Society for Medical Oncology.
MLA
Czuczman M S, Leonard J P, Jung S, Johnson J L, Hsi E D, Byrd J C and Cheson B D. Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness. : Annals of oncology : official journal of the European Society for Medical Oncology. 112018.